II International Symposium on Innovations in the Treatment of Coronary Artery Disease and Structural Heart Disease

The II International Symposium on Innovations in the Treatment of Coronary Artery Disease and Structural Heart Disease will take place on July 31st, 2019 at the Syrian-Lebanese Hospital in São Paulo.

Se acerca el IV Simposio de Cardiopatía Isquémica del ICBA

This event seeks to provide a better understanding of indications and clinical and interventional strategies for complex heart conditions, such as left main coronary artery obstructions, patients with acute coronary syndromes, patients at high risk for bleeding and an indication for coronary intervention, as well as percutaneous approaches to aortic stenosis (TAVR), mitral regurgitation, left atrial appendage closure, foramen ovale closure, etc.

Topics will be addressed dynamically and interactively, with clinical case presentations, conferences, and discussions, so as to provide information and improve the integration of new technologies into clinical practice.

Furthermore, this event will feature first-class international faculties.

Special Benefits

50% Off in Registration Fees for SOLACI Members!

SOLACI members registering for this event enjoy a 50% discount in the registration fee. Select “SOLACI member” in the registry system for this event and follow the instructions.

Those attending the SOLACI-SBHCI 2019 Congress will have a 50% discount on registrations to the II International Symposium of Innovations in the Treatment of Coronary and Structural Diseases

More information and registration HERE (this website is in portuguese language)

If you have questions or queries, write to secretaria.iep@hsl.org.br

This symposium is destined to: healthcare professionals, cardiologists and interventional cardiologists, cardiovascular surgeons, students, residents, nurses, and multidisciplinary teams seeking to stay updated on the latest transcatheter cardiology strategies.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACC 2026: SURViV Trial Results – Exclusive Presentation and Analysis with Dr. Dimytri Siqueira

Following the presentation of the SURViV trial in the Late Breaking Clinical Trials sessions at the American College of Cardiology Congress, Dr. Dimytri Siqueira...

SOLACI Technicians Webinar – Ultrasound Pulses + Calcium = Coronary Lithotripsy

The Latin American Society of Interventional Cardiology (SOLACI) invites you to participate in a new Live SOLACI Webinar specially designed for technicians, nurses, and...

COMPLICAT 2026: Collaborative learning to address complications in congenital and structural heart disease

Free online course in Spanish5 webinars in 2026 COMPLICAT 2026 returns with its second edition, consolidating itself as an innovative academic space dedicated to the...

CHIP LATAM | Chapter 2 – Mexico: Complications Workshop

The Latin American Society of Interventional Cardiology invites the entire medical community to participate in a virtual workshop on complications organized by SOLACI’s Complex...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2026 | CHIP-BCIS3: Impella use as support in high-risk complex PCI

The use of percutaneous ventricular support during high-risk complex PCI has been proposed as a strategy to prevent hemodynamic deterioration in patients with severe...

ACC 2026 | ORBITA-CTO: PCI in chronic total occlusions and stable angina — the randomized trial we were missing?

Percutaneous coronary intervention (PCI) for chronic total occlusions (CTO) remains a topic of ongoing debate in stable angina, with persistent uncertainty regarding its role...

ACC 2026 | FAST III: vFFR vs FFR in physiology-guided revascularization of intermediate coronary lesions

Physiological assessment of intermediate coronary lesions remains a cornerstone in decision-making for coronary revascularization. Although FFR continues to be one of the guideline-recommended references,...